Skip to main content
Log in

Comment on: “Healthy Decisions: Towards Uncertainty Tolerance in Healthcare Policy”

  • Letter to the Editor
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Grutters JP, van Asselt MB, Chalkidou K, Joore MA. Healthy decisions: towards uncertainty tolerance in healthcare policy. Pharmacoeconomics. 2015;33(1):1–4.

    Article  PubMed  Google Scholar 

  2. Luce RD, Raiffa H. Games and decisions: introduction and critical survey. Courier Corporation; 2012.

  3. Salomon JA, Weinstein MC, Goldie SJ. Taking account of future technology in cost effectiveness analysis. BMJ. 2004;329(7468):733–6.

    Article  PubMed Central  PubMed  Google Scholar 

  4. Gandjour A. Germany’s decision rule for setting ceiling prices of drugs: a comparative analysis with other decision rules. Appl Health Econ Health Policy. 2011;9(2):65–71.

    Article  PubMed  Google Scholar 

  5. Gandjour A. Presenting Germany’s drug pricing rule as a cost-per-QALY rule. Health Care Manag Sci. 2012;15(2):103–7.

    Article  PubMed  Google Scholar 

  6. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Allgemeine Methoden. Version 4.2. Köln; 2015.

  7. Gandjour A. Comment on: “are current cost-effectiveness thresholds for low- and middle-income countries useful? Examples from the world of vaccines”. Pharmacoeconomics. 2014;32(12):1245–6.

    Article  PubMed  Google Scholar 

  8. Gandjour A, Gafni A. The German method for setting ceiling prices for drugs: in some cases less data are required. Expert Rev Pharmacoecon Outcomes Res. 2011;11(4):403–9.

    Article  PubMed  Google Scholar 

  9. Graff Zivin J. Cost-effectiveness analysis with risk aversion. Health Econ. 2001;10:499–508.

    Article  Google Scholar 

  10. Hoel M. Allocating health care resources when people are risk averse with respect to life time. Health Econ. 2003;12(7):601–8.

    Article  PubMed  Google Scholar 

  11. Al MJ, Feenstra TL, van Hout BA. Optimal allocation of resources over health care programmes: dealing with decreasing marginal utility and uncertainty. Health Econ. 2005;14:655–67.

    Article  PubMed  Google Scholar 

  12. Elbasha EH. Risk aversion and uncertainty in cost-effectiveness analysis: the expected-utility, moment-generating function approach. Health Econ. 2005;14(5):457–70.

    Article  PubMed  Google Scholar 

  13. Gandjour A. Pharmaceutical risk-sharing agreements. Pharmacoeconomics. 2009;27(5):431–2.

    Article  PubMed  Google Scholar 

  14. Gandjour A. Prioritizing comparative effectiveness research: are drug and implementation trials equally worth funding? Pharmacoeconomics. 2011;29(7):555–61.

    PubMed  Google Scholar 

  15. Berger L, Bleichrodt H, Eeckhoudt L. Treatment decisions under ambiguity. J Health Econ. 2013;32(3):559–69.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

There are no potential conflicts of interest. The author did not receive funding for writing this manuscript.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Afschin Gandjour.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gandjour, A. Comment on: “Healthy Decisions: Towards Uncertainty Tolerance in Healthcare Policy”. PharmacoEconomics 33, 981–982 (2015). https://doi.org/10.1007/s40273-015-0317-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40273-015-0317-4

Keywords

Navigation